Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials Communications|April 27, 2018
Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studiesAlfred Saah, Oliver Bautista, Alain Luxembourg, et al.
Statistics in Medicine|October 21, 2003
Over-ruling a group sequential boundary--a stopping rule versus a guidelineK K Gordon Lan, John M Lachin, Oliver Bautista
Contemporary Clinical Trials|March 10, 2015
Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccineAlain Luxembourg, Oliver Bautista, Erin Moeller, et al.
Contemporary Clinical Trials|April 15, 2021
Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervalsHedy Teppler, Oliver Bautista, , et al.
Obstetrics and Gynecology|October 30, 2025
Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional SurgeryElmar Joura, Susanne K Kjaer, Oliver Bautista, et al.
Clinical and Vaccine Immunology : CVI|April 21, 2012
Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccineKatie Matys, Sara Mallary, Oliver Bautista, et al.
Human Vaccines & Immunotherapeutics|October 7, 2024
Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian womenSusanne K Kjaer, Thea E Hetland Falkenthal, Karin Sundström, et al.
Human Vaccines & Immunotherapeutics|September 28, 2018
Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccineAna Maria Guevara, Eugenio Suarez, Alejandro Victoria, et al.
Pediatrics|July 9, 2024
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV VaccineNicola P Klein, Amy Wiesner, Oliver Bautista, et al.
Vaccine|September 29, 2015
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccineSuzanne M Garland, Tak-Hong Cheung, Shelly McNeill, et al.
Pageof 2